| Literature DB >> 30609770 |
Carmelo Minardi1, Roberta Minacapelli2, Pietro Valastro3, Francesco Vasile4, Sofia Pitino5, Piero Pavone6, Marinella Astuto7, Paolo Murabito8.
Abstract
Seizures are defined as a transient occurrence of signs and symptoms due to the abnormal, excessive, or synchronous neuronal activity in the brain characterized by abrupt and involuntary skeletal muscle activity. An early diagnosis, treatment, and specific medical support must be performed to prevent Status Epilepticus (SE). Seizure onset, especially in the child population, is related to specific risk factors like positive family history, fever, infections, neurological comorbidity, premature birth, mother's alcohol abuse, and smoking in pregnancy. Early death risk in children without neurological comorbidity is similar to the general population. Diagnosis is generally based on the identification of continuous or recurrent seizures but Electroencephalogram (EEG) evaluation could be useful if SE condition is suspected. The main goal of therapy is to counteract the pathological mechanism which occurs in SE before neural cells are irreversibly damaged. According to the latest International Guidelines and Recommendations of seizure related diseases, a schematic and multi-stage pharmacological and diagnostic approach is proposed especially in the management of SE and its related causes in children. First measures should focus on early and appropriate drugs administration at adequate dosage, airway management, monitoring vital signs, Pediatric Intensive Care Unit (PICU) admission, and management of parent anxiety.Entities:
Keywords: children; seizures; status epilepticus
Year: 2019 PMID: 30609770 PMCID: PMC6352402 DOI: 10.3390/jcm8010039
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Classification of seizure types-expanded version [7].
| Seizure Types | Prominent Features | |||
|---|---|---|---|---|
| Focal Onset | Awake/impaired awarness | Motor onset Automatism Atonic Clonic Epileptic spasm Hyperkinetic Myocloniconic Tonic | Non motor onset Autonomic Behavior arrest Cognitive Emotional Sensory | Focal to bilateral tonic clonic |
| Generalized Onset | Motor Tonic-clonic Tonic Clonic Myoclonic Myoclonic-tonic-clonic Myoclonic-atonic Epileptic spasm | Non motor Typical Atypical Myoclonic Eyelid myoclonia | ||
| Unknown Onset | Motor Tonic-clonic Epileptic spasm | Non motor Behavior arrest | Unclassified |
Classification of the epilepsies [9].
| Co-morbidities | ||
| Seizures types Focal Generalized Unknown | Epilepsy types Focal Generalized Combined generalized and focal Unknown | Epilepsy syndromes |
| Etiology | ||
Semeiologic classification of Status Epilepticus (SE).
| Prominent motor symptoms | Convulsive SE | Generalized convulsive | |
| Focal onset evolving into bilateral convulsive SE | |||
| Unknown whether focal or generalized | |||
| Myoclonic SE | With coma | ||
| Without coma | |||
| Focal motor | Repeated focal motor seizures (Jacksonian) | ||
| Epilepsia partialis continua (EPC) | |||
| Adversive status | |||
| Oculoclonic status | |||
| Ictal paresis | |||
| Tonic status | |||
| Hyperkinetic SE | |||
| Without prominent motor symptoms or Non-convulsive status epilepticus (NCSE) | NCSE with coma | ||
| NCSE without coma | Generalized | Typical absence status | |
| Atypical absence status | |||
| Myoclonic absence status | |||
| Focal | Without impairment of consciousness | ||
| Aphasic status | |||
| With impairment of consciousness | |||
| Unknown whether focal or generalized | Autonomic SE | ||
Etiologic classification of SE.
| Known | Acute | Stroke, Intoxication, Malaria, Encephalitis, etc. |
| Remote | Post traumatic, Post encephalitic, Post stroke, etc. | |
| Progressive | Brain tumors, Lafora’s disease, Dementias | |
| SE in defined electro clinical syndromes | ||
| Unknown | Cryptogenetic | |
Electroencephalogram EEG related SE classification.
| Location | Generalized |
| Lateralized | |
| Bilateral independent | |
| Multifocal | |
| Pattern | Periodic discharges |
| Number of phases | |
| Spike-and-wave/sharp-and-wave plus subtypes. | |
| Morphology | Sharpness |
| Number of phases | |
| Absolute and relative amplitude | |
| Polarity | |
| Time related features | Prevalence |
| Frequency | |
| Duration | |
| Onset | |
| Dynamics | |
| Modulation | Stimulus-induced vs. spontaneous |
| Effect of intervention on EEG |
Seizure age-related classification.
| SE occurring in neonatal and infantile-onset epilepsy syndromes | Tonic status (Ohtahara’s Syndrome, West’s syndrome) |
| Myoclonic status in Dravet syndrome | |
| Focal status | |
| Febrile SE | |
| SE occurring mainly in childhood and adolescent | Autonomic in early onset benign childhood occipital epilepsy Panayiotopoulos Syndrome) |
| NCSE in specific childhood epilepsy syndromes and etiologys (Ring Cromosome 20, Angelman Syndrome) | |
| Tonic status in Lennox–Gastaut syndrome | |
| Myoclonic status in progressive myoclonus epilepsies | |
| Electrical status epilepticus in slow wave sleep (ESES) | |
| Aphasic status in Landau–Kleffner Syndrome | |
| SE occurring mainly in adolescents and adulthood | Myoclonic status in juvenile myoclonic epilepsy |
| Absence status in juvenile myoclonic epilepsy | |
| Myoclonic status in Down syndrome | |
| SE occurring mainly in the elderly | Myoclonic status in Alzheimer’s disease |
| NCSE in Creutzfeldt–Jakob disease | |
| De novo (or relapsing) absence status of later life |
Pharmacological therapy.
| T1 | T2 | T3 | |||
|---|---|---|---|---|---|
| Early phase Status Epilepticus | Clear Status Epilepticus | Refractory Status Epilepticus | |||
| Hospitalization in PICU | |||||
|
| Lorazepam: 0.1 mg/kg. |
| Phenytoin: 15 mg/kg IV. |
| Propofol: 2–4 mg/kg in bolus. |
| Diazepam: 0.5–1mg/kg IV | Valproic acid: 20 mg/kg (velocity: 5 mg/kg/min) | Midazolam: 0.2 mg/kg (dose max 5 mg). Continuous infusion 0.1–0.3 mg/kg/h | |||
| Clonazepam: 1 mg bolus IV (max 0.5 mg/min). | Levetiracetam: 30 mg/kg (velocity: 5 mg/kg/min) | Thiopental: 3–5 mg/kg IV. | |||
| Fenobarbital: 10 mg/kg (range 10–20) bolus IV. | Lacosamide (>16 years): loading dose 200 mg. | Pentobarbital: 5–15 mg/kg bolus IV. Continuous infusion to maintain burst suppression (0.5–3 mg/kg/h) | |||